 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Zhengzhou Humanwell BIOCELL biotechnology Co., Ltd |
| Street 1: | #28 the First Ave, Jingkai Area |
| Street 2: | |
| City: | Zhengzhou |
| Province: | Henan |
| Post Code: | 450016 |
| Country: | China |
| Phone: | 8613871460230 |
| Organization Email: | jifangxing@cnbiocell.com |
| Web Site: | http://www.cnbiocell.com |
| Other Online Presence: | |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | Private sector |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | |
| Organization Type - Primary: | Private Sector |
| Organization Type - Secondary: | Company |
| Organization Description: | |
| BIOCELL, founded in 1988, specialized in the R&D, manufacturing and marketing of IVD (in vitro diagnostic) reagents, have obtained 153 products’ registration certificates in China, including five series,such as enzyme, immune luminescence?microbial series. In dedication of screening LTBI in China, BIOCELL launched two products in China in 2016: BIOCELL® TB-IGRA(qualitative detection of the Mycobacterium tuberculosis specific T-cell immune response in human fresh peripheral intravenous anticoagulant blood) and BIOCELL® TB-SPOT(ELISPOT assay for the quantitative determination based on T-cell immune response towards Mycobacterium tuberculosis-specific antigen) Comparing to QFT, BIOCELL® have the same quality, less labor time and lower cost. Up to now, BIOCELL® has been exporting to countries like India and South Korea in different ways, including OEM and local administration. |
|
| Do you know about the UNHLM declaration: | |
Specializations / Areas of Work | |
|
Provision of drugs, diagnostics and commodities Research and Development Technical Assistance |
Other Organization Information | |
| Total number of staff in your organization: | 100 + |
| Number of full-time staff who are directly involved with TB: | 11 - 25 |
| Number of part-time staff who are directly involved with TB: | 26 - 50 |
| Number of volunteers who are directly involved with TB: | 11 - 25 |
| How did you hear about the Stop TB Partnership: | Internet search |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | |
| Why do you wish join the Stop TB Partnership: | Network with other partners |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | No |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| BIOCELL have been cooperating with CDC of Henan, Hubei and Xinjiang Province for large screening LTBI since 2016. Large number of Class-3 hospitals in the middle-west of China have added BIOCELL(R) products to the standard LTBI diagnose list. BIOCELL has also beginning to export BIOCELL(R) TB-IGRA and TB-SPOT to India and South Korea with competitive cost and quality, helping the countries to diagnose LTBI in a large scale of people. |
|
Geographical Reach | |
| Which country is your headquarters located in: | China |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
China India Republic of Korea |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
New Diagnostics: BIOCELL(R) TB products are the most economic, convenient and sensitive way to diagnose LTBI in China. We are exploring new methods to further diagnose LTBI and active TB. New products will be launched in 2-3 years. |
|
Declaration | |
| Declaration of interests: No conflicts of interest were delacred. | |
| Application date: | May 25, 2017 |
| Last updated: | May 30, 2017 |